Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315)

European Journal of Cancer(2026)10.1016/j.ejca.2026.116265Source: DataRank Database

Institutional variability in testing for actionable genetic alterations in patients with stage IIIB/C or IV non-small cell lung cancer: A real-world study from the German prospective, observational, multicenter CRISP registry (AIO-TRK-0315) is a research paper published in European Journal of Cancer (2026). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Free full text

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (16 grants)Impact (FWCI 0.00)OA: hybridTopics (32)IDs (PubMed, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (20)

Horst-Dieter Hummel ORCID,Konrad Kokowski,Corinna Elender,Christian Grah ORCID,Stefan Zacharias

Live enrichment

PubMed:41633313 OpenAlex:https://openalex.org/W7126217203

AstraZeneca PLC

Bristol-Myers Squibb Foundation

MSD Sharp & Dohme GmbH

Pfizer BV

Boehringer Ingelheim GmbH

Eli Lilly and Company

Novartis Pharma GmbH

Daiichi Sankyo Europe GmbH

Gilead Sciences Inc

Janssen Global Services LLC

Regeneron Pharmaceuticals Inc

Celgene Corporation

F Hoffmann-La Roche AG

GSK plc

Amgen Inc

Takeda Pharmaceutical Company Limited

FWCI

0.00

Citation Percentile

0.1%

hybridLicense: cc-by

journalhttps://doi.org/10.1016/j.ejca.2026.116265

publisherhttps://doi.org/10.1016/j.ejca.2026.116265

publisherhttps://api.elsevier.com/content/article/PII:S0959804926000456?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0959804926000456?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/41633313

Fields of Study

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

MeSH Terms

AdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungFemaleGenetic TestingGermanyHumansLung NeoplasmsMaleMiddle AgedMutationNeoplasm StagingProspective StudiesRegistriesBiomarkers, Tumor

Keywords

GermanStage (stratigraphy)Genetic testingLungPatient careNon-small cell lung cancer (NSCLC)Access To CarePractice PatternsMetastatic DiseaseMolecular TestingReal-world DataInstitutional VariabilityPrecision Oncology

Sustainable Development Goals

SDG 0: Good health and well-being